HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advanced Polymer Systems

This article was originally published in The Rose Sheet

Executive Summary

Firm plans to change labeling for its Exact benzoyl peroxide acne medication vanishing cream and acne cleanser after receiving an April 13 warning letter from FDA. The label modifications, which are awaiting an agency response, eliminate the claim that Exact contains "microscopic sponges that time-release benzoyl peroxide" because FDA pointed out that the topical acne drug monograph does not provide for the "time release or continuous release" of anti-acne products. APS said it also plans to change other aspects of the labeling to be in compliance with the monograph

Latest Headlines
See All
UsernamePublicRestriction

Register

RS000508

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel